Literature DB >> 10785543

Cardiovascular effects of endocannabinoids--the plot thickens.

G Kunos1, Z Járai, K Varga, J Liu, L Wang, J A Wagner.   

Abstract

Cannabinoids, the bioactive ingredients of the marijuana plant, are best known for their psychoactive properties, but they also influence other physiological processes, such as cardiovascular variables. Endocannabinoids are recently identified lipid mediators that act as natural ligands at cannabinoid receptors and mimic most of the biological effects, including the cardiovascular actions, of plant-derived cannabinoids. In experimental animals, the most prominent component of the cardiovascular effects of cannabinoids is prolonged hypotension and bradycardia. This review focuses on the possible mechanisms underlying these effects. The emerging evidence suggesting that endocannabinoids may be involved in the peripheral regulation of vascular tone under certain conditions is also discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10785543     DOI: 10.1016/s0090-6980(00)00056-3

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  11 in total

Review 1.  Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice.

Authors:  G Kunos; S Bátkai
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

Review 2.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

3.  Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels.

Authors:  J Grainger; G Boachie-Ansah
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

4.  Exogenous anandamide protects rat brain against acute neuronal injury in vivo.

Authors:  M van der Stelt; W B Veldhuis; G W van Haaften; F Fezza; T Bisogno; P R Bar; G A Veldink; J F Vliegenthart; V Di Marzo; K Nicolay
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

5.  The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression.

Authors:  Nathalie Niederhoffer; Karin Schmid; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-23       Impact factor: 3.000

6.  Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity.

Authors:  M van der Stelt; W B Veldhuis; P R Bär; G A Veldink; J F Vliegenthart; K Nicolay
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

Review 7.  Cannabinoids and neuroprotection.

Authors:  R I Grundy; M Rabuffetti; M Beltramo
Journal:  Mol Neurobiol       Date:  2001 Aug-Dec       Impact factor: 5.590

8.  Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats.

Authors:  Torsten Pfitzer; Nathalie Niederhoffer; Bela Szabo
Journal:  Br J Pharmacol       Date:  2004-06-28       Impact factor: 8.739

9.  Analysis of the respiratory effects of cannabinoids in rats.

Authors:  Karin Schmid; Nathalie Niederhoffer; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-10       Impact factor: 3.000

Review 10.  Cannabinoids, endocannabinoids, and related analogs in inflammation.

Authors:  Sumner H Burstein; Robert B Zurier
Journal:  AAPS J       Date:  2009-02-06       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.